Log in to search using one of your social media accounts:


Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels

Irisin is a hormone released mainly from skeletal muscle after exercise which increases adipose tissue energy expenditure. Adipocytes can also release irisin after exercise, acting as a local adipokine to indu...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research

Related Links:

Purpose: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. Methods: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preope...
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
Source: Endocrine - Category: Endocrinology Source Type: research
Sodium glucose co‐transporter 2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are antihyperglycaemic agents with weight‐lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a GLP‐1RA (≥12 weeks) were evaluated in this phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints included the change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), bodyweight, systolic blood pressure (SBP), ...
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: BRIEF REPORT Source Type: research
Condition:   Type 2 Diabetes Mellitus Interventions:   Biological: MEDI0382;   Biological: Placebo;   Drug: Dapaglifozin Sponsor:   MedImmune LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: Exenatide LAR;   Drug: Dulaglutide Sponsor:   University of Guadalajara Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
One thing that's clear is that type 2 diabetes is on the rise, especially among younger people across the developed world.
Source: WebMD Health - Category: Consumer Health News Source Type: news
It is “imperative” that patients diagnosed with type 2 diabetes during their 20s, 30s and 40s receive significant support on optimising their treatment and self-management skills, warn researchers in light of a new study on mortality risk.
Source: Nursing Times - Category: Nursing Source Type: news
A study inDiabetologia reports that early diagnosis of type-2 diabetes is associated with an increased risk of death from heart attack and stroke. Daily Mail
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
TYPE 2 DIABETES symptoms include passing more urine than usual and feeling tired all the time. If the condition is left untreated, a number of other health problems can follow, so it ’s important to recognise all the signs - including feeling very thirsty.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
FRIDAY, Feb. 23, 2018 -- A type 2 diabetes diagnosis that comes early in life carries a deadly load of health risks, new research shows. It was associated with a 60 percent higher relative risk of dying from heart disease or stroke. Not only that,...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Expenditures | Heart | Hormones | Sports Medicine